Clinical features of severe patients infected with 2019 novel coronavirus: a systematic review and meta-analysis

Huang, Daozheng; Lian, Xihua; Song, Feier; Ma, Huan; Lian, Zhiwen; Liang, Yuanfeng; Qin, Tiehe; Chen, Wei; Wang, Shouhong

doi:10.21037/atm-20-2124

Cited by 85 publications

(111 citation statements)

References 20 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Fever was common in studies reported in China and these studies have a lower mortality. [2,13] This observation is in line with the statement that fever is a marker of optimal host response to an injury. Interestingly, some studies showed that fever was present in only about 50% of patients and the same studies revealed a mortality of about 50%.…”

Section: Discussionsupporting

confidence: 86%

“…Severe COVID 19 was seen predominantly in males; six of the studies showed a range of 15% -48% of females and an average of 29.5% female. [2,[10][11][12][13][14] It means; less than 1 out of 5 patients with severe COVID-19 will be a woman. At the best interpretation of 4 out of 6 studies that provided the patients ages, the patients median age was 64 years and older.…”

Section: Discussionmentioning

confidence: 99%

“…[10][11][12]14] Six of the studies revealed multiple comorbidities. [2,[10][11][12][13][14] Diabetes mellitus, arterial hypertension and COPD were the most reported comorbidities.…”

Section: Discussionmentioning

confidence: 99%

“…[8] Therefore, there were seven publications for our review. [2,[9][10][11][12][13][14] Total severe COVID-19 cases included by gender and age Our study included a total 1,863 patients, the median age was 63.5 years and range was 49-70 years. A total 370 (19.8%) were females.…”

Section: Selected Publicationsmentioning

confidence: 99%

“…Four studies were from the USA, two from China and one from Italy. [2,[9][10][11][12][13][14] Reported comorbidities The comorbidities reported in six studies were as follows: diabetes mellitus 254 (13.6%), arterial hypertension 604/1818 (33.2%), chronic obstructive pulmonary disease (COPD) 58/1779 (3.3%), chronic kidney disease (CKD) 51/1636 (3.1%).…”

Section: Selected Publicationsmentioning

confidence: 99%

See 4 more Smart Citations

Severe COVID-19

Chawala¹

2020

JRI

View full text Add to dashboard Cite

Introduction: There are substantial variabilities of the clinical characteristics and outcomes of severe coronavirus disease (COVID-19) creating difficulty to do an optimal assessment of this condition. We reviewed the current English literature to quantify the findings of baselines characteristics and health outcomes of patients with severe COVID-19 primarily with acute respiratory distress syndrome (ARDS). Methods: We examined only studies that assessed patients with proven COVID-19 by RT-PCR by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with at least one of the following severity criteria: severe COVID-19, treated in the ICUs, ARDS and/or invasive mechanical ventilation (IMV) treatment. We assessed the quality of the studies according to the National Heart, Lung and Blood Institute, Study Quality Assessment Tools. Results: Seven of 39 studies fulfilled the inclusion criteria. These seven studies included a total 1,863 patients, the median age was 63.5 years (49-70). A total 370 (19.8%) were females. Four studies were from the USA, two from China and one from Italy. Comorbidities were reported in six studies. Fever was reported in five studies and it was present in 159 out of 272 patients. Cough and shortness of breath (SOB) were reported in four studies, they were present in 111 out of 142 and 100 out of 142 of patients respectively. The median of total lymphocytes was reported in five studies with a range of 400-889/ul. IMV ranged from 15% to 100% and mortality ranged from 14.6% to 88%. In a subgroup analysis by countries, patients from the US showed more comorbidities, higher percent of IMV and mortality. The assessment quality score of the seven studies was (5), for a total score of (8). Conclusions: Severe COVID-19 was predominantly seen in male patients who were 60 years and older associated with comorbidities. Most of the patients were admitted at the ICU, needed IMV support due to ARDS and had a mortality range of 14.6-88%.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

“…[10][11][12]14] Six of the studies revealed multiple comorbidities. [2,[10][11][12][13][14] Diabetes mellitus, arterial hypertension and COPD were the most reported comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Section: Selected Publicationsmentioning

confidence: 99%

Section: Selected Publicationsmentioning

confidence: 99%

See 3 more Smart Citations

Severe COVID-19

Chawala¹

2020

JRI

View full text Add to dashboard Cite

show abstract

Early prediction of COVID‐19 severity using extracellular vesicle COPB2

Fujita

Hoshina

Matsuzaki

et al. 2021

J of Extracellular Vesicle

View full text Add to dashboard Cite

The clinical manifestations of COVID‐19 vary broadly, ranging from asymptomatic infection to acute respiratory failure and death. But the predictive biomarkers for characterizing the variability are still lacking. Since emerging evidence indicates that extracellular vesicles (EVs) and extracellular RNAs (exRNAs) are functionally involved in a number of pathological processes, we hypothesize that these extracellular components may be key determinants and/or predictors of COVID‐19 severity. To test our hypothesis, we collected serum samples from 31 patients with mild COVID‐19 symptoms at the time of their admission for discovery cohort. After symptomatic treatment without corticosteroids, 9 of the 31 patients developed severe/critical COVID‐19 symptoms. We analyzed EV protein and exRNA profiles to look for correlations between these profiles and COVID‐19 severity. Strikingly, we identified three distinct groups of markers (antiviral response‐related EV proteins, coagulation‐related markers, and liver damage‐related exRNAs) with the potential to serve as early predictive biomarkers for COVID‐19 severity. As the best predictive marker, EV COPB2 protein, a subunit of the Golgi coatomer complex, exhibited significantly higher abundance in patients remained mild than developed severe/critical COVID‐19 and healthy controls in discovery cohort (AUC 1.00 (95% CI: 1.00‐1.00)). The validation set included 40 COVID‐19 patients and 39 healthy controls, and showed exactly the same trend between the three groups with excellent predictive value (AUC 0.85 (95% CI: 0.73‐0.97)). These findings highlight the potential of EV COPB2 expression for patient stratification and for making early clinical decisions about strategies for COVID‐19 therapy.

show abstract

Immunogenicity of COVID‐19 vaccines in patients with diverse health conditions: A comprehensive systematic review

Cho

Park

Kim

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

It remains unclear how effective COVID-19 vaccinations will be in patients with weakened immunity due to diseases, transplantation, and dialysis. We conducted a systematic review comparing the efficacy of COVID-19 vaccination in patients with solid tumor, hematologic malignancy, autoimmune disease, inflammatory bowel disease, and patients who received transplantation or dialysis. A literature search was conducted twice using the Medline/PubMed database. As a result, 21 papers were included in the review, and seropositivity rate was summarized by specific type of disease, transplantation, and dialysis. When different papers studied the same type of patient group, a study with a higher number of participants was selected.Most of the solid tumor patients showed a seropositivity rate of more than 80% after the second inoculation, but a low seropositivity was found in certain tumors such as breast cancer. Research in patients with certain types of hematological malignancy and autoimmune diseases has also reported low seropositivity, and this

show abstract

Clinical features of severe patients infected with 2019 novel coronavirus: a systematic review and meta-analysis

Cited by 85 publications

References 20 publications

Severe COVID-19

Severe COVID-19

Early prediction of COVID‐19 severity using extracellular vesicle COPB2

Immunogenicity of COVID‐19 vaccines in patients with diverse health conditions: A comprehensive systematic review

Contact Info

Product

Resources

About